TORONTO, ONTARIO — (Marketwired) — 09/25/13 — BioExx Specialty Proteins Ltd. (“BioExx” or the “Company”) (TSX: BXI), today announced that the Toronto Stock Exchange (the “TSX”) has informed the Company that it is reviewing the eligibility for continued listing of the Company–s common shares on the TSX. The Company has been granted 60 days to comply with all the requirements for continued listing. If the Company cannot demonstrate that it meets all of the TSX ongoing listing requirements on or before November 25, 2013, the Company–s common shares will be delisted.
BioExx–s management is currently reviewing the situation and evaluating various courses of action to meet the TSX requirements before the end of the 60 day period.
About BioExx Specialty Proteins Ltd.
Headquartered in Toronto, Canada, BioExx is focused on the separation of oil and high-value proteins from oilseeds for global food, beverage, nutrition, and other markets. BioExx employs trade secret, patented and patent-pending technologies to enable the improved separation of proteins from oilseeds. BioExx believes that these processes cumulatively have the potential to make a valuable contribution to global food and protein supply while maintaining an environmentally sustainable footprint.
To find out more about BioExx Specialty Proteins Ltd. (TSX: BXI), please visit .
The statements made in this press release include forward-looking statements that involve a number of risks and uncertainties. These statements relate to future events or future performance and reflect management–s current expectations and assumptions. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements, such as the economy, generally, competition in its target markets, the demand for BioExx–s products, the availability of funding, the efficacy of its technology, and the anticipated costs of BioExx–s plant construction and operation. These forward-looking statements are made as of the date hereof and BioExx does not assume any obligation to update or revise them to reflect new events or circumstances. Actual events or results could differ materially from BioExx–s expectations and projections.
Contacts:
BioExx Specialty Proteins Ltd.
John MacDonald
Interim Chief Executive Officer
(416) 588-4442